Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 3,675 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Excision Clear all
Completed Phase 2 Interventional Results available

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

NCT00084656
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
ipilimumab, Tyrosinase/gp100/MART-1 Peptides
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 120 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Results available

Study of Diclofenac Capsules to Treat Dental Pain

NCT00985439
View directory record Official record
Conditions
Dental Pain
Interventions
Diclofenac Test (lower dose), Diclofenac Test (upper dose), Celecoxib 400 mg, Placebo
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting Phase 2 Interventional

Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma

NCT07040280
View directory record Official record
Conditions
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Cutaneous Dysplastic Nevus
Interventions
Biopsy Procedure, Biospecimen Collection, Placebo Administration, Sulforaphane
Procedure · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

MIPE for Pilonidal Disease

NCT03772873
View directory record Official record
Conditions
Pilonidal Disease, Pilonidal Cyst/Fistula, Pilonidal Sinus Without Abscess, Pilonidal Cyst Without Abscess, Pilonidal Cyst and Sinus Without Abscess, Pilonidal Abscess, Pilonidal Sinus With Abscess, Pilonidal Dimple With Abscess, Pilonidal Fistula With Abscess, Pilonidal Sinus Infected, Pilonidal Cyst With Sinus, Pilonidal Cyst and Sinus With Abscess, Pilonidal Disease of Natal Cleft Abscess
Interventions
minimally invasive pilonidal excision
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
2 Years to 25 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
10
States / cities
Chicago, Illinois • Park Ridge, Illinois • Portland, Maine + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated Not applicable Interventional Results available

TECR & ECM Placement for Esophageal High Grade Dysplasia

NCT02396745
View directory record Official record
Conditions
Barrett Esophagus, Esophagus, High Grade Dysplasia
Interventions
Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))
Device
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated Phase 1 Interventional

FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer

NCT06338657
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, PEOX-based Polymer Encapsulated Paclitaxel FID-007, Tumor Resection
Procedure · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting Phase 3 Interventional

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

NCT04865939
View directory record Official record
Conditions
Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma Ureter
Interventions
sterile water irrigation, Gemcitabine
Procedure · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Catalyst CSR Shoulder System for Semi or Total Shoulder Arthroplasty

NCT04968405
View directory record Official record
Conditions
Osteoarthritis Shoulder, Avascular Necrosis of the Head of Humerus, Rheumatoid Arthritis Shoulder
Interventions
Catalyst CSR Total Shoulder System
Device
Lead sponsor
Catalyst OrthoScience
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
3
States / cities
Royal Oak, Michigan • Portland, Oregon • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Active, not recruiting Early Phase 1 Interventional

Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube

NCT03771651
View directory record Official record
Conditions
Fallopian Tube Cancer, Fallopian Tube Infection
Interventions
Aspirin 81 mg
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting No phase listed Observational

Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms

NCT07377929
View directory record Official record
Conditions
Benign Prostatic Hypertrophy (BPH), Lower Urinary Track Symptoms
Interventions
Survey using a questionnaire.
Other
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated Phase 2 Interventional Results available

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

NCT03108495
View directory record Official record
Conditions
Cervical Carcinoma
Interventions
LN-145, LN-145 + pembrolizumab
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated Phase 3 Interventional

A Study With Imlifidase in Anti-GBM Disease

NCT05679401
View directory record Official record
Conditions
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions
Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
Drug · Procedure
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

NCT06365619
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

IUD Self-Removal: Evaluating an Online Guide for Self-removal in Clinical and Non-clinical Settings

NCT06042556
View directory record Official record
Conditions
IUD, Contraception
Interventions
IUD self-removal guide
Other
Lead sponsor
University of Washington
Other
Eligibility
14 Years and older · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated No phase listed Observational

Ultrafiltration Therapy Registry Using Aquadex (ULTRA-Peds)

NCT04644731
View directory record Official record
Conditions
Fluid Overload
Interventions
Aquadex™ System
Device
Lead sponsor
Nuwellis, Inc.
Industry
Eligibility
Up to 21 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Birmingham, Alabama • Palo Alto, California • Hollywood, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 2 Interventional

Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer

NCT01553019
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Proton radiation, Gemcitabine
Radiation · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Jacksonville, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)

NCT01078987
View directory record Official record
Conditions
Nephrogenic Fibrosing Dermopathy, Nephrogenic Systemic Fibrosis
Interventions
Plasmapheresis
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2012
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting Phase 1 Interventional

A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer

NCT05521698
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Bicalutamide, Biopsy Procedure, Biospecimen Collection, Questionnaire Administration, Transurethral Resection of Bladder Tumor
Drug · Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Tucson, Arizona • Los Angeles, California • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 2 Interventional

Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver

NCT00030563
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
irinotecan hydrochloride, adjuvant therapy, conventional surgery, radiofrequency ablation
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Cleveland, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma

NCT00203892
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
modified CEA peptide (10mcg), modified CEA peptide (100mcg), modified CEA peptide (1000mcg)
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated Phase 2 Interventional Results available

Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy

NCT00766636
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Radiation Therapy, Erlotinib, Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional Results available

Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation

NCT01569763
View directory record Official record
Conditions
Menorrhagia
Interventions
Aurora Endometrial Ablation, Rollerball Ablation/Resection
Device
Lead sponsor
Minerva Surgical, Inc.
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
8
States / cities
Chandler, Arizona • Phoenix, Arizona • Newburgh, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Early Phase 1 Interventional Results available

Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer

NCT00734994
View directory record Official record
Conditions
Transitional Cell Carcinoma of Bladder, Superficial Bladder Cancer
Interventions
Hyperthermia System, Mitomycin C
Device · Drug
Lead sponsor
Mark Dewhirst
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quick Start Insertion of Mirena and ParaGard

NCT01730911
View directory record Official record
Conditions
Bleeding, Cramping, Pregnancy With IUD in Place, IUD Expulsion, IUD Removal
Interventions
Text message
Other
Lead sponsor
Columbia University
Other
Eligibility
Female only
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 17, 2026, 10:20 PM EDT